California's Huya And China Medical City Create Alliance To Develop Chinese Pharmaceutical Projects
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Huya Bioscience International has entered into a strategic alliance to help accelerate the development of innovative R&D projects originating in China Medical City, in the Taizhou National Medical Hi-tech Development Zone
You may also be interested in...
Reverse Innovation In China: An Interview With HUYA CEO Mireille Gillings
Eight years ago, HUYA’s CEO Mireille Gillings began screening compounds developed in China to bring them to global markets. Nowadays, the company says it has a database with more than 12,000 compounds and 2,000 biomarkers from China.
China On The Road Toward Becoming World Center For Drug Innovation, Say Huya Bioscience Leaders
BEIJING - The science-savvy leaders of China, along with the Western-educated Chinese chemists and biologists migrating back here, are helping lay the foundation for the country one day to become a world center for innovation in developing new-generation medicines, according to senior executives at the San Diego-headquartered Huya Bioscience
China On The Road Toward Becoming World Center For Drug Innovation, Say Huya Bioscience Leaders
BEIJING - The science-savvy leaders of China, along with the Western-educated Chinese chemists and biologists migrating back here, are helping lay the foundation for the country one day to become a world center for innovation in developing new-generation medicines, according to senior executives at the San Diego-headquartered Huya Bioscience